இயக்குனர் ஜநரல் இந்தியன் சபை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இயக்குனர் ஜநரல் இந்தியன் சபை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இயக்குனர் ஜநரல் இந்தியன் சபை Today - Breaking & Trending Today

Lallan Miss is a touching story based on the complicated layers of transgender life

Lallan Miss is a touching story based on the complicated layers of transgender life
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.

New Delhi , Dinesh Patnaik , Padmashri Shovana Narayan , Vani Prakashan , Padma Shri Shovana Narayan , Rama Pandey , Aditi Maheshwari , Shri Vikas Kumar Jha , Shri Sachidanand Joshi , Sachidanand Joshi , Lallan Hijra , Shri Dinesh Patnaik , Vikas Kumar Jha , Hotel Ambassador , Indira Gandhi National Center , Indian Council Of Cultural Relations , Lallan Mis , Rajya Sabha , Padma Vibhushan Sonal Mansingh , Director General Indian Council , Cultural Relations , Member Secretary Indira Gandhi National Center , புதியது டெல்ஹி , தினேஷ் பாதநைக் , வாணி பிரகாஷன் , ராமா பாண்டே ,

Covaxin third phase clinical trials results out, 77.8 per cent effective against Covid-19

Covaxin third phase clinical trials results out, 77.8 per cent effective against Covid-19
Covaxin has also been found to be 65.2 percent effective against the dreaded Delta variant of Coronavirus, which is becoming the dominant strain of the virus across the world.
Share Via Email
| A+A A-
By Express News Service
HYDERABAD: Covaxin, the Covid-19 vaccine developed by Hyderabad-based vaccine maker Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been found to be 77.8 percent effective in the Phase-III clinical trials.
Also, Covaxin has been found to be 93.4% effective against severe symptomatic form of Covid-19 and 63.6 percent effective against asymptomatic Covid-19. ....

Andhra Pradesh , United States , Priya Abraham , Krishna Ella , Balram Bhargava , National Institute Of Virology , Indian Council Of Medical Research , News Service , Department Of Health Research , Express News , Bharat Biotech , Indian Council , Medical Research , Data Safety Monitoring Board , Managing Director , Secretary Department , Health Research , Director General Indian Council , Use Listing , ஆந்திரா பிரதேஷ் , ஒன்றுபட்டது மாநிலங்களில் , கிருஷ்ணா எல்லா , பால்ராம் பார்கவா , தேசிய நிறுவனம் ஆஃப் வைராலஜி , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , செய்தி சேவை ,

Covaxin 77.8% effective against Covid-19: Bharat Bio - The Hindu BusinessLine

Covaxin 77.8% effective against Covid-19: Bharat Bio - The Hindu BusinessLine
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Andhra Pradesh , United States , Krishna Ella , Balram Bhargava , Indian Council Of Medical Research , Department Of Health Research , Managing Director , Bharat Biotech , Secretary Department , Health Research , Director General Indian Council , Medical Research , Data Safety Monitoring Board , ஆந்திரா பிரதேஷ் , ஒன்றுபட்டது மாநிலங்களில் , கிருஷ்ணா எல்லா , பால்ராம் பார்கவா , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , துறை ஆஃப் ஆரோக்கியம் ஆராய்ச்சி , நிர்வகித்தல் இயக்குனர் , பாரத் பயோடெக் , செயலாளர் துறை , ஆரோக்கியம் ஆராய்ச்சி , இயக்குனர் ஜநரல் இந்தியன் சபை , மருத்துவ ஆராய்ச்சி , தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை ,

Covaxin 77.8% effective against symptomatic Covid-19: Bharat Biotech

Bharat Biotech says that the final efficacy analysis of Covaxin shows it to be 77.8 per cent effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission.
This paves the way for Covaxin to get World Health Organisation s approval for its inclusion in the Emergency Use List of Covid-19 vaccines.
The company added that the analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19. The safety analysis demonstrates that adverse events reported were similar to placebo, with 12 per cent of the subjects experiencing commonly known side effects and less than 0.5 per cent of them feeling serious adverse effects. The efficacy data further demonstrates 63.6 per cent protection ag ....

Krishna Ella , Balram Bhargava , National Institutes Of Health , Indian Council Of Medical Research , Department Of Health Research , World Health Organisation , Bharat Biotech , Emergency Use List , National Institutes , Data Safety Monitoring Board , Managing Director , Covid Vaccines , Secretary Department , Health Research , Director General Indian Council , Medical Research , கிருஷ்ணா எல்லா , பால்ராம் பார்கவா , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , துறை ஆஃப் ஆரோக்கியம் ஆராய்ச்சி , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , பாரத் பயோடெக் , அவசரம் பயன்பாடு பட்டியல் , தேசிய நிறுவனங்கள் , தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை ,

Coronavirus: Covaxin Overall 77.8% Effective, Claims Bharat Biotech In Final Phase 3 Data

Covaxin has received emergency use authorizations in 16 countries, Bharat Biotech said.
Highlights
The vaccine offers 65.2 per cent protection against Delta variant
Phase 3 trials were conducted on 130 symptomatic Covid patients
New Delhi:
Bharat Biotech s Covaxin is overall 77.8 per cent effective against Covid, the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed.
The vaccine offers 65.2 per cent protection , it said, against the rapidly emerging Delta variant.
It was also found to be 93.4 per cent effective against severe symptomatic COVID-19, the company said.
Covaxin is a whole virus inactivated vaccine against SARS-CoV2, developed by Bharat Biotech in partnership with ICMR and NIV Pune. ....

Andhra Pradesh , Bharat Biotech , Krishna Ella , Balram Bhargava , Suchitra Ella , Indian Council Of Medical Research , Department Of Health Research , Largest Efficacy , Print Data Published , Managing Director , Secretary Department , Health Research , Director General Indian Council , Medical Research , Genome Valley , Japanese Encephalitis , ஆந்திரா பிரதேஷ் , பாரத் பயோடெக் , கிருஷ்ணா எல்லா , பால்ராம் பார்கவா , சூச்சித்ர எல்லா , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , துறை ஆஃப் ஆரோக்கியம் ஆராய்ச்சி , நிர்வகித்தல் இயக்குனர் , செயலாளர் துறை , ஆரோக்கியம் ஆராய்ச்சி ,